Ragweed MATA MPL

BIOLOGICAL2 trials

Sponsors

Allergy Therapeutics

Conditions

Type I Hypersensitivity

Phase 1

Assessment of Residual Allergenicity of Ragweed Pollen Allergoid With Monophosphoryl Lipid A (MPL) Using Skin Prick Testing

CompletedNCT00116285

Allergy TherapeuticsType I Hypersensitivity

Start: 2005-06-30End: 2005-06-30Target: 12Updated: 2010-06-17

Phase 3

Efficacy and Safety/Tolerability of Ragweed MATA MPL

CompletedNCT00423787

Allergy TherapeuticsType I Hypersensitivity

Start: 2007-03-31End: 2008-03-31Updated: 2010-06-17